Published in J Am Acad Dermatol on August 01, 2003
Efalizumab binding to the LFA-1 alphaL I domain blocks ICAM-1 binding via steric hindrance. Proc Natl Acad Sci U S A (2009) 1.13
Retracted Association of cytokine gene polymorphisms with psoriasis in cases from the nile delta of egypt. Indian J Dermatol (2011) 1.08
Current concepts in the pathogenesis of psoriasis. Indian J Dermatol (2009) 0.98
The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res (2007) 0.84
Immunobiologics in the treatment of psoriasis. Clin Immunol (2007) 0.79
Novel immunobiologics for psoriasis. Indian J Pharmacol (2008) 0.75
Tolerability, pharmacokinetics and pharmacodynamics of CMAB001, an anti-CD11a antibody, in Chinese healthy volunteers and psoriatic patients. Acta Pharmacol Sin (2012) 0.75
Association Between Psoriasis and Subclinical Atherosclerosis: A Meta-Analysis. Medicine (Baltimore) (2016) 0.75
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol (2008) 3.95
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA (2011) 3.29
Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis (2012) 2.29
Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch Dermatol (2005) 2.28
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol (2011) 2.03
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol (2008) 1.99
Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol (2009) 1.94
A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol (2003) 1.77
Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents. J Am Acad Dermatol (2009) 1.76
AJC editor's consensus: psoriasis and coronary artery disease. Am J Cardiol (2008) 1.54
Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol (2002) 1.54
Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy. J Am Acad Dermatol (2009) 1.48
The editor's roundtable: psoriasis, inflammation, and coronary artery disease. Am J Cardiol (2008) 1.45
A series of critically challenging case scenarios in moderate to severe psoriasis: a Delphi consensus approach. J Am Acad Dermatol (2009) 1.45
Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol (2008) 1.43
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol (2007) 1.35
Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol (2005) 1.34
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol (2003) 1.16
Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol (2004) 1.15
Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol (2010) 1.10
Definitions of measures of effect duration for psoriasis treatments. Arch Dermatol (2005) 1.07
Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol (2007) 1.03
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg (2010) 0.99
Lessons learned from psoriatic plaques concerning mechanisms of tissue repair, remodeling, and inflammation. J Investig Dermatol Symp Proc (2006) 0.92
Differential abilities of central nervous system resident endothelial cells and astrocytes to serve as inducible antigen-presenting cells. Blood (2002) 0.91
A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol (2006) 0.91
Evaluation of tissue-engineered skin (human skin substitute) and secondary intention healing in the treatment of full thickness wounds after Mohs micrographic or excisional surgery. Dermatol Surg (2002) 0.90
Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol (2006) 0.89
Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol (2010) 0.88
Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat (2007) 0.88
Long-term efficacy of biologics in the treatment of psoriasis: what do we really know? Dermatol Ther (2009) 0.86
Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol (2003) 0.84
An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol (2012) 0.82
Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol (2006) 0.81
Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol (2013) 0.81
Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2013 MauiDerm Meeting. J Clin Aesthet Dermatol (2013) 0.79
Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther (2005) 0.79
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. J Dermatolog Treat (2007) 0.78
Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther (2004) 0.78
Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci (2007) 0.78
Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf (2002) 0.78
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2. Dermatol Ther (Heidelb) (2012) 0.77
From laboratory to clinic: rationale for biologic therapy. Dermatol Clin (2004) 0.77
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1. Dermatol Ther (Heidelb) (2012) 0.76
Patient education and advocacy groups: a means to better outcomes? Arch Dermatol (2005) 0.76
Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol (2010) 0.76
Treating psoriasis with adalimumab. Ther Clin Risk Manag (2008) 0.76
Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Core Evid (2010) 0.75
Strategies for treatment with anti-tumor necrosis factor agents in psoriasis: maintaining efficacy and safety for the long haul. Arch Dermatol (2010) 0.75
Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. J Cutan Med Surg (2005) 0.75
The new psoriasis pathway: toward a unified theory of immunopathogenesis. Expert Rev Clin Immunol (2007) 0.75
Duration of remission of biologic agents for chronic plaque psoriasis. J Drugs Dermatol (2007) 0.75